FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003
Burlington, MA, June 7, 2021 – Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA
June 7, 2021
Burlington, MA, June 7, 2021 – Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA
Details on the available COVID-19 vaccines Source: Center for Disease Control and Prevention (CDC)
Dr. James Hendrix, LuMind IDSC’s Chief Scientific Officer, along with a team of Down syndrome experts recently published an article
May 13, 2021 LuMind IDSC’s Chief Scientific Officer, James Hendrix, and a team of dedicated researchers and clinicians have published
May 3, 2021 LuMind IDSC supported the T21RS COVID-19 Initiative that brought about the original survey and the resulting analysis,
March 9, 2021 (Burlington, MA): LuMind IDSC Foundation, the National Down Syndrome Society (NDSS), and pharmaceutical leader Eli Lilly and
As life expectancy of people with Down syndrome (DS) increases, so does the risk of Alzheimer’s disease (AD). Identifying symptoms
As medical systems plan for a possible flood of COVID-19 patients, healthcare professionals in the United States may draft guidance
On December 20, ACIP updated interim vaccine allocation recommendations. In Phase 1b, COVID-19 vaccine should be offered to persons aged
The Down Syndrome Medical Interest Group (DSMIG) has released this position statement about the COVID-19 vaccine. This statement addresses some